Hikma stock gains after Barclays raises rating and target

Published on 09/09/2026 at 15:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hikma stock closed at 1,628 pence on the London Stock Exchange on September 8, 2026 after Barclays lifted its rating to equal weight with a 1,700 pence price target. Fresh earnings data show improved profitability, giving investors more confidence in the margin story.

Hikma, GB00B128J450, Illustration mit AI erstellt.

Hikma Pharmaceuticals PLC stock (ISIN GB00B128J450) finished trading at 1,628 pence on the London Stock Exchange on September 8, 2026, up about 1.8 percent from the previous session, after Barclays upgraded its stance on the shares to equal weight and set a price target of 1,700 pence as reported on September 8, 2026.

Barclays upgrade provides new signal

According to IT BOLTWISE on September 8, 2026, Barclays raised its rating on Hikma from underweight to equal weight and increased its published stance with a price target of 1,700 pence.

The distance from the close of 1,628 pence on September 8, 2026 to the 1,700 pence target is 72 pence, implying about 4.4 percent potential upside if the shares were to reach that level.IT BOLTWISE The article notes that Hikma shares were among the gainers in the FTSE 250 index environment on September 8, 2026 as investors reacted to the change in stance.IT BOLTWISE

Recent financial performance underpins the call

Fresh fundamental figures give investors more context for the rating change. Data compiled by Investing.com show that Hikma reported earnings per share of 1.02 dollars and revenue of about 1.73 billion dollars in its most recent results release dated August 6, 2026, covering the latest reporting period.

Those figures represent growth compared with the previous full year. The same financial overview indicates that Hikma’s total revenue increased from 3,127 million dollars in fiscal year 2024 to 3,349 million dollars in fiscal year 2025, a rise of about 7.1 percent.Investing.com Over the same period, operating profit increased from 614 million dollars to 648 million dollars, an advance of roughly 5.5 percent, while operating margin stayed close to 19 percent.Investing.com

Key balance sheet ratios also frame the valuation. The Investing.com summary lists an EBITDA of 842 million dollars for Hikma, alongside a debt-to-equity ratio of 77.11 percent and a return on equity of 15.41 percent for the latest reported period.Investing.com The same source cites a dividend yield of 4.02 percent based on trailing twelve-month distributions, with an annualized payout of about 64.13 dollars per share equivalent and a five-year dividend growth rate of 10.59 percent, underscoring Hikma’s track record of returning cash to shareholders.Investing.com

Stock trades below recent highs

Price data from the same Investing.com page indicate that Hikma shares recently traded at 1,547 pence on the BATS Europe venue on September 9, 2026, down 3.19 percent on the day with a move of minus 51 pence. Investing.com The same snapshot shows an intraday trading range between 1,546 pence and 1,589 pence on that date.Investing.com

The 52-week range reported by Investing.com stretches from a low of 15.88 pounds to a high of 18.65 pounds for Hikma shares, equivalent to 1,588 pence and 1,865 pence respectively, placing the recent 1,547 pence level below the middle of that band and roughly 17 percent under the 52-week high.Investing.com On September 8, 2026, Hikma’s closing price of 1,628 pence on the London Stock Exchange therefore stood closer to the upper portion of the recent trading corridor but still meaningfully below the 52-week high, which helps explain the room Barclays sees up to its 1,700 pence target.

Product mix and regulatory backdrop remain key

The IT BOLTWISE article describes Hikma as a pharmaceutical group with a significant focus on generic medicines and injectable drugs, particularly in hospital markets across Europe, the Middle East and the United States.IT BOLTWISE Many of these products are used in therapeutic areas such as anti-infectives, anesthetics and cardiovascular treatments, which typically benefit from standardized treatment pathways and long-term relationships with hospital and health-system customers.IT BOLTWISE

At the same time, Hikma’s operations are exposed to regulatory risk and the need for continued investment in manufacturing quality, compliance and product approvals. The IT BOLTWISE analysis points out that high capital expenditure and regulatory demands mean margins act as a stress test for the business model, making Barclays’ focus on a stabilizing margin profile central to its neutral rating shift.IT BOLTWISE For investors, upcoming product launches, tenders and regulatory milestones will be important catalysts to watch against the backdrop of Barclay’s 1,700 pence price target and the company’s recent earnings trajectory.

Hikma stock price snapshot

Hikma stock last closed at 1,628 pence on the London Stock Exchange on September 8, 2026, which was about 1.8 percent higher than the previous close and left the shares roughly 4.4 percent below Barclays’ 1,700 pence price target.